Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Beelitz – page 117

1 845 clinical trials in Beelitz, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Beelitz at a glance
1 845
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 845 trials in Beelitz

Open in trial search

Arteriosclerosis

Not recruiting

Study on DFV890 and MAS825 for Reducing Inflammation in Adults with Coronary Heart Disease and Clonal Hematopoiesis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Arumakimig
  • Sponsor:Novartis Pharma AG

Multiple sclerosis+2

Not recruiting

Study on the Effects of a Higher Dose of Ocrelizumab for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Study on Nipocalimab for Adults with Warm Autoimmune Hemolytic Anemia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Study on the Effectiveness and Safety of Remibrutinib Compared to Placebo and Omalizumab in Adults with Chronic Spontaneous Urticaria Uncontrolled by Antihistamines

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Omalizumab
  • Sponsor:Novartis Pharma AG

Study of Belumosudil and Prednisone for Patients Aged 12 and Older with Newly Diagnosed Chronic Graft Versus Host Disease

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Pustular psoriasis

Not recruiting

Study on Long-Term Spesolimab Treatment for Patients with Generalized Pustular Psoriasis from Previous Trials

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Leo Pharma A/S

Study on Durvalumab and Platinum-Based Drug Combination for Patients with Stage IIB-IIIB Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:AstraZeneca AB

Study on Alectinib and Durvalumab for Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Pneumonia

Not recruiting

Study on AON-D21 for Patients with Severe Community-Acquired Pneumonia in Intensive Care

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aon-D21
  • Sponsor:Aptarion Biotech AG

Study Comparing Standard Chemotherapy with CPX-351 for Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) and Intermediate or Adverse Genetics

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Universitaetsklinikum Ulm AöR

Study Comparing Entrectinib and Crizotinib for Patients with Advanced Non-Small Cell Lung Cancer with ROS1 Gene Changes, With or Without Brain Metastases

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Crizotinib
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Beelitz

What the registry says about research in the country

01 Neurological Disorders Research

Innovative clinical trials focusing on Multiple System Atrophy (MSA), evaluating new therapeutic compounds aimed at slowing disease progression and improving patient outcomes.

  • Novel Treatment Development
  • Disease Progression Management
  • Clinical Efficacy Studies

Multiple investigational treatments are being assessed through controlled clinical studies.

02 Movement Disorders Research

Research initiatives targeting Progressive Supranuclear Palsy (PSP), with studies designed to evaluate innovative therapeutic approaches for this rare neurological condition.

  • Disease Modification Strategies
  • Safety Assessment Protocols
  • Long-term Efficacy Evaluation

Comprehensive 52-week studies are underway to assess new treatment options.

03 Parkinson's Disease Studies

Specialized research focusing on GBA1 gene-related Parkinson's Disease, investigating targeted treatments to address motor function and disease progression.

  • Genetic-based Treatments
  • Motor Function Assessment
  • Pharmacodynamic Studies

Advanced clinical trials utilizing standardized rating scales to measure treatment effectiveness.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.